OM:IZAFE B

Stock Analysis Report

Executive Summary

iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally.

Snowflake

Fundamentals

Overvalued with weak fundamentals.

Share Price & News

How has iZafe Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.3%

IZAFE B

-3.8%

SE Healthcare Services

2.1%

SE Market


1 Year Return

-37.1%

IZAFE B

7.6%

SE Healthcare Services

16.4%

SE Market

Return vs Industry: IZAFE B underperformed the Swedish Healthcare Services industry which returned 7.6% over the past year.

Return vs Market: IZAFE B underperformed the Swedish Market which returned 16.4% over the past year.


Shareholder returns

IZAFE BIndustryMarket
7 Day2.3%-3.8%2.1%
30 Day19.6%3.4%4.2%
90 Day3.9%12.8%4.5%
1 Year-37.1%-37.1%7.7%7.6%21.4%16.4%
3 Year-44.7%-44.7%-14.5%-14.8%34.5%14.1%
5 Year53.9%53.9%117.0%104.3%60.3%26.2%

Price Volatility Vs. Market

How volatile is iZafe Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is iZafe Group undervalued compared to its fair value and its price relative to the market?

3.41x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IZAFE B's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IZAFE B's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IZAFE B is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: IZAFE B is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IZAFE B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IZAFE B is good value based on its PB Ratio (3.4x) compared to the SE Healthcare Services industry average (7.2x).


Next Steps

Future Growth

How is iZafe Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iZafe Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has iZafe Group performed over the past 5 years?

-26.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IZAFE B is unprofitable, and losses have increased over the past 5 years at a rate of -26.7% per year.

Accelerating Growth: Unable to compare IZAFE B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IZAFE B is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (11.4%).


Return on Equity

High ROE: IZAFE B has a negative Return on Equity (-65.64%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IZAFE B is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IZAFE B is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is iZafe Group's financial position?


Financial Position Analysis

Short Term Liabilities: IZAFE B's short term assets (SEK3.2M) do not cover its short term liabilities (SEK26.4M)

Long Term Liabilities: IZAFE B's short term assets (3.2M) do not cover its long term liabilities (6.0M)


Debt to Equity History and Analysis

Debt Level: IZAFE B's debt to equity ratio (41.3%) is considered high

Reducing Debt: IZAFE B's debt to equity ratio has increased from 17.8% to 41.3% over the past 5 years.


Balance Sheet

Inventory Level: IZAFE B has a low level of unsold assets or inventory.

Debt Coverage by Assets: IZAFE B's debt is not covered by short term assets (assets are 0.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IZAFE B has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IZAFE B has less than a year of cash runway if free cash flow continues to reduce at historical rates of -74.1% each year


Next Steps

Dividend

What is iZafe Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.8%industryaverage1.7%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IZAFE B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IZAFE B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IZAFE B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IZAFE B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IZAFE B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of iZafe Group's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Anders Segerström (34yo)

0.8yrs

Tenure

0

Mr. Anders Segerström serves as the CEO at MediRätt AB (publ) since 2019. Mr. Segerström has been in leading company roles in the fields of business development, sales and management since 2005. In 2017, A ...


Management Age and Tenure

0.8yrs

Average Tenure

53yo

Average Age

Experienced Management: IZAFE B's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

5.1yrs

Average Tenure

44yo

Average Age

Experienced Board: IZAFE B's board of directors are considered experienced (5.1 years average tenure).


Insider Trading

Insider Buying: IZAFE B insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buykr80,00002 Oct 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares20,000
Max Pricekr4.00
Buykr41,00001 Oct 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max Pricekr4.10
Buykr6,60011 Sep 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares2,000
Max Pricekr3.30
Buykr32,80010 Sep 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max Pricekr3.28
Buykr135,00012 Jun 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares30,000
Max Pricekr4.50
Buykr60,34510 Jun 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares13,500
Max Pricekr4.47
Buykr1,994,99723 May 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares385,135
Max Pricekr5.18
Buykr128,05516 May 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares28,500
Max Pricekr4.50
Buykr275,00008 May 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares50,000
Max Pricekr5.50
Buykr40,00003 Apr 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares8,000
Max Pricekr5.00
Buykr51,00001 Apr 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max Pricekr5.10
Buykr51,00028 Mar 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max Pricekr5.10
Buykr76,50026 Mar 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares15,000
Max Pricekr5.10
Buykr52,50021 Mar 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max Pricekr5.25
Buykr51,20014 Mar 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max Pricekr5.12
Buykr36,89012 Mar 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares7,000
Max Pricekr5.27
Buykr550,00024 Jan 19
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares100,000
Max Pricekr5.50
Buykr70,00005 Dec 18
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max Pricekr7.00
Buykr35,00026 Oct 18
Carl Merner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares5,000
Max Pricekr7.00

Ownership Breakdown


Management Team

  • Barbro Sjönell

    Co-Founder

    • Tenure: 0yrs
  • Mikael Svensson (53yo)

    Chief Operating Officer

    • Tenure: 2.8yrs
  • Tobias Johansson

    Head of Sales & VP

    • Tenure: 0.8yrs
  • Anders Segerström (34yo)

    Chief Executive Officer

    • Tenure: 0.8yrs
  • Göran Hermanson (66yo)

    Chief Operating Officer

    • Tenure: 0.8yrs

Board Members

  • Göran Sjönell

    Director

    • Tenure: 10.9yrs
  • Barbro Sjönell

    Co-Founder

    • Tenure: 0yrs
  • Carl Merner (44yo)

    Chairman of the Board

    • Tenure: 0.8yrs
  • Carl Sjönell (48yo)

    Director

    • Tenure: 8.5yrs
  • Calle Sjönell

    Director

    • Tenure: 0yrs
  • Viveca Gyberg (36yo)

    Director

    • Tenure: 1.8yrs

Company Information

iZafe Group AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: iZafe Group AB (publ)
  • Ticker: IZAFE B
  • Exchange: OM
  • Founded: 2008
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: kr86.707m
  • Shares outstanding: 19.29m
  • Website: https://www.izafe.se

Location

  • iZafe Group AB (publ)
  • Stockholmsvägen 33
  • Lidingö
  • Stockholm County
  • 181 33
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IZAFE BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKApr 2011
M02BST (Boerse-Stuttgart)YesClass B SharesDEEURApr 2011

Biography

iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. The company offers Dosell, a drug d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 21:15
End of Day Share Price2019/10/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.